GB201709403D0 - Compounds for treating sarcoma - Google Patents

Compounds for treating sarcoma

Info

Publication number
GB201709403D0
GB201709403D0 GBGB1709403.8A GB201709403A GB201709403D0 GB 201709403 D0 GB201709403 D0 GB 201709403D0 GB 201709403 A GB201709403 A GB 201709403A GB 201709403 D0 GB201709403 D0 GB 201709403D0
Authority
GB
United Kingdom
Prior art keywords
compounds
treating sarcoma
sarcoma
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1709403.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Priority to GBGB1709403.8A priority Critical patent/GB201709403D0/en
Publication of GB201709403D0 publication Critical patent/GB201709403D0/en
Priority to TW107120396A priority patent/TW201919618A/zh
Priority to ES18733530T priority patent/ES2970224T3/es
Priority to US16/621,885 priority patent/US11576899B2/en
Priority to CA3067065A priority patent/CA3067065A1/en
Priority to PCT/EP2018/065668 priority patent/WO2018229133A1/en
Priority to EP18733530.2A priority patent/EP3638232B1/en
Priority to KR1020197037099A priority patent/KR20200014791A/ko
Priority to JP2019568646A priority patent/JP2020523355A/ja
Priority to ARP180101623A priority patent/AR112144A1/es
Priority to MX2019015212A priority patent/MX2019015212A/es
Priority to AU2018285822A priority patent/AU2018285822B2/en
Priority to BR112019026463-9A priority patent/BR112019026463A2/pt
Priority to IL271020A priority patent/IL271020A/en
Priority to US18/108,736 priority patent/US12257237B2/en
Priority to US19/066,910 priority patent/US20250375424A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1709403.8A 2017-06-13 2017-06-13 Compounds for treating sarcoma Ceased GB201709403D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB1709403.8A GB201709403D0 (en) 2017-06-13 2017-06-13 Compounds for treating sarcoma
BR112019026463-9A BR112019026463A2 (pt) 2017-06-13 2018-06-13 tinostamustina para uso no tratamento de sarcoma
EP18733530.2A EP3638232B1 (en) 2017-06-13 2018-06-13 Tinostamustine for use in treating sarcoma
JP2019568646A JP2020523355A (ja) 2017-06-13 2018-06-13 肉腫を処置することへの使用のためのチノスタムスチン
US16/621,885 US11576899B2 (en) 2017-06-13 2018-06-13 Tinostamustine for use in treating sarcoma
CA3067065A CA3067065A1 (en) 2017-06-13 2018-06-13 Tinostamustine for use in treating sarcoma
PCT/EP2018/065668 WO2018229133A1 (en) 2017-06-13 2018-06-13 Tinostamustine for use in treating sarcoma
TW107120396A TW201919618A (zh) 2017-06-13 2018-06-13 用於治療肉瘤的化合物
KR1020197037099A KR20200014791A (ko) 2017-06-13 2018-06-13 육종 치료에 사용하기 위한 티노스타무스틴
ES18733530T ES2970224T3 (es) 2017-06-13 2018-06-13 Tinostamustina para su uso en el tratamiento del sarcoma
ARP180101623A AR112144A1 (es) 2017-06-13 2018-06-13 Compuestos para el tratamiento del sarcoma
MX2019015212A MX2019015212A (es) 2017-06-13 2018-06-13 Compuestos para el tratamiento del sarcoma.
AU2018285822A AU2018285822B2 (en) 2017-06-13 2018-06-13 Tinostamustine for use in treating sarcoma
IL271020A IL271020A (en) 2017-06-13 2019-11-28 Tinostemustine for the treatment of sarcoma
US18/108,736 US12257237B2 (en) 2017-06-13 2023-02-13 Tinostamustine for use in treating sarcoma
US19/066,910 US20250375424A1 (en) 2017-06-13 2025-02-28 Tinostamustine for use in treating sarcoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709403.8A GB201709403D0 (en) 2017-06-13 2017-06-13 Compounds for treating sarcoma

Publications (1)

Publication Number Publication Date
GB201709403D0 true GB201709403D0 (en) 2017-07-26

Family

ID=59358374

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1709403.8A Ceased GB201709403D0 (en) 2017-06-13 2017-06-13 Compounds for treating sarcoma

Country Status (14)

Country Link
US (3) US11576899B2 (enExample)
EP (1) EP3638232B1 (enExample)
JP (1) JP2020523355A (enExample)
KR (1) KR20200014791A (enExample)
AR (1) AR112144A1 (enExample)
AU (1) AU2018285822B2 (enExample)
BR (1) BR112019026463A2 (enExample)
CA (1) CA3067065A1 (enExample)
ES (1) ES2970224T3 (enExample)
GB (1) GB201709403D0 (enExample)
IL (1) IL271020A (enExample)
MX (1) MX2019015212A (enExample)
TW (1) TW201919618A (enExample)
WO (1) WO2018229133A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709405D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4868824A (en) 1987-12-28 1989-09-19 American Telephone And Telegraph Company Measurement of missed start-up rate and missed message rate
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US5719548A (en) 1995-01-09 1998-02-17 Brunswick Bowling & Billiards Corporation Bowling scoring console
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
ES2210769T3 (es) 1997-06-13 2004-07-01 Cydex Inc. Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US20020076409A1 (en) 2000-07-12 2002-06-20 March Carl J. Method for treating cancer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2423868C (en) 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
CN1764648A (zh) 2003-01-13 2006-04-26 安斯泰来制药有限公司 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
EP1599449A2 (en) 2003-02-25 2005-11-30 TopoTarget UK Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
US20060270730A1 (en) 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CA2561617A1 (en) 2004-04-05 2005-10-20 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
SI1901729T1 (sl) 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
NZ575394A (en) 2006-10-20 2012-01-12 Icos Corp Compositions of chk1 inhibitors and cyclodextrin
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
WO2008063644A1 (en) 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
CN101084876A (zh) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009067453A1 (en) 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US8987468B2 (en) 2008-02-04 2015-03-24 The Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
CN104224703A (zh) 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
MX2011003751A (es) 2008-10-08 2011-04-27 Cephalon Inc Procesos para preparar bendamustina.
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
ME02254B (me) * 2009-01-23 2015-12-31 Euro Celtique Sa Derivati hidroksamske kiseline
AU2010217297A1 (en) 2009-02-25 2011-10-20 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011017448A1 (en) 2009-08-05 2011-02-10 The Trustees Of The University Of Pennsylvania Use of histone deacetylase inhibitors for treatment of autoimmune diseases
CN101928234B (zh) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
US9889147B2 (en) 2010-04-16 2018-02-13 Cellact Pharma Gmbh Analogues of etoposide for the treatment of tumours
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
UA110853C2 (uk) * 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
CN102993102B (zh) 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
EP2758052B9 (en) 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
ES2616242T3 (es) 2011-09-28 2017-06-12 Euro-Celtique S.A. Derivados de mostaza de nitrógeno
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
NZ630314A (en) 2014-02-18 2016-03-31 Celgene Corp Combination therapy for hematological malignancies
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
CN107438436A (zh) 2014-12-05 2017-12-05 摩德纳和雷焦艾米利亚大学 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合
US20180311215A1 (en) 2015-10-20 2018-11-01 Hangzhou TINO Pharma Co., Ltd. Pharmaceutical composition and preparation method therefor
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma
US20240252472A1 (en) 2023-01-25 2024-08-01 Purdue Pharma L.P. Combinations for treating cancer
US20240366569A1 (en) 2023-05-05 2024-11-07 Purdue Pharmaceutical Products L.P. Combinations for treating cancer

Also Published As

Publication number Publication date
EP3638232A1 (en) 2020-04-22
JP2020523355A (ja) 2020-08-06
US12257237B2 (en) 2025-03-25
WO2018229133A1 (en) 2018-12-20
EP3638232B1 (en) 2023-12-13
KR20200014791A (ko) 2020-02-11
ES2970224T3 (es) 2024-05-27
US11576899B2 (en) 2023-02-14
AR112144A1 (es) 2019-09-25
AU2018285822A1 (en) 2019-12-19
BR112019026463A2 (pt) 2020-07-14
US20200113870A1 (en) 2020-04-16
AU2018285822B2 (en) 2024-01-04
CA3067065A1 (en) 2018-12-20
MX2019015212A (es) 2020-08-17
US20250375424A1 (en) 2025-12-11
US20230277507A1 (en) 2023-09-07
TW201919618A (zh) 2019-06-01
IL271020A (en) 2020-01-30
EP3638232C0 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
GB201704325D0 (en) Compounds
IL271018A (en) Compounds for the treatment of triple-negative breast cancer
GB201709402D0 (en) Compounds for treating t-pll
ZA201906047B (en) Compounds for treating tuberculosis
IL272805B (en) Pyridylpyridone compounds
GB201707938D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201702221D0 (en) Compounds
PT3448853T (pt) Compostos para modular aquaporinas
GB201706162D0 (en) Compounds
PT3589637T (pt) Compostos úteis para inibir ror-gamma-t
PL3589638T3 (pl) Związki użyteczne do hamowania ror-gamma-t
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201709404D0 (en) Compounds for treating TNBC
GB201721752D0 (en) Compounds
GB201709559D0 (en) Compounds for treating lupus
GB201709642D0 (en) Compounds
GB201708845D0 (en) Compounds
GB201708848D0 (en) Compounds
GB201708846D0 (en) Compounds
GB201707966D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)